Event Panel Schedule


Presentations and Panels
Keynote: Cur­rent Cap­i­tals Mar­kets Overview
Webcast
D6e82cb28471e3f7c3a83d663271015b_aedd23f2ea6dce11cc3f7e32a801908b_120_120
Jefferies LLC
Gil Bar-Nahum, Managing Director / Jefferies LLC
Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment…

Presentations and Panels
What It Takes: A Suc­cess­ful U.S. IPO in A New Vir­tu­al World
Webcast
Cc9a654752def02be043792ce41909eb_a355e2b2ea6515a0155e865930be5d20_120_120
Solebury Trout
Thomas Hoffmann, Managing Director / Solebury Trout
Tommy’s knowledge of the European markets and his deep relationships with the European investment community has helped many of Solebury Trout’s clients expand their reach into Europe. Conversely, he also assists clients based outside the United…
643216a2970110d7d23e6b0fbd166a9d_87928d4c58ba8cd9eb61ebb8d71e76ee_120_120
CureVac AG
Franz-Werner Haas, Chief Executive Officer, Chief Operating Officer / CureVac AG
Franz-Werner Haas joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions…
981084b3bc9b87289883a803810edb6c_add9443180c8382b63a6071badc87c0a_120_120
Goodwin Procter LLP
Robert Puopolo, Partner / Goodwin Procter LLP
Rob Puopolo, a partner in Goodwin’s Life Sciences practice, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, hedge funds and investment banks that focus on these companies.
0fa91081304d7a82916b6559284b3c41_b47f4eefb14e855d8d34042fca8e922d_120_120
SVB Leerink
Gabriel P. Cavazos, Managing Director / SVB Leerink
Gabriel Cavazos has been with Leerink Swann in the Healthcare Banking Division since 2008. Prior to that he worked in M&A at JP Morgan and previously at Merck and Pfizer. He has a BSc in Cellular & Molecular Biology from the University of…
6e131dc27690bed353dbe4ea5195a8d0_42c96a7e4558ec2ef89cec7ba84542e9_120_120
Solebury Capital
Bill Kadel, Vice President / Solebury Capital
Bill Kadel is a Vice President at Solebury Capital focusing on equity capital markets within Healthcare and Life Sciences. In this role, Bill advises clients on ECM strategy around IPOs, FOs, SPACs and other equity linked transactions. Prior to…

Presentations and Panels
Al­ter­na­tives to IPOs: Re­v­erse Merg­ers, Di­rect List­ings, SPACs, Cross-Over Fi­nanc­ings, and De-Risk­ing Strate­gies
Webcast
Fe151d92e5cfef31e5c9872e6b74f35b_320c7239cd8e90320bcd16d689e3f7fd_120_120
Goodwin Procter LLP
Edwin O'Connor, Partner / Goodwin Procter LLP
Edwin O’Connor, a partner in Goodwin’s Technology Companies Group, has a broad-based capital markets practice and represents issuers and underwriters in public and private corporate finance transactions, both in the United States and internationally…
E3d5aaff1b68f80a9656e97a4185b563_723ebef7301f0c3d390c7d14738031bd_120_120
Immatics NV
Thomas Ulmer, CFO / Formerly with Immatics Biotechnologies GmbH
Thomas Ulmer joined Immatics Biotechnologies GmbH in April 2018 from the Merck Group, where he was Chief Financial Officer of the Allergopharma Business Unit. During his tenure with Allergopharma he was the key architect for defining and implementing…
D6e82cb28471e3f7c3a83d663271015b_aedd23f2ea6dce11cc3f7e32a801908b_120_120
Jefferies LLC
Gil Bar-Nahum, Managing Director / Jefferies LLC
Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment…
7243aaab96a8860be70914e198bc1778_5b2c5225d955c22e61ecb17669cc94e3_120_120
Solebury Capital
John Haynor, Managing Director / Solebury Capital
John Haynor is a Managing Director at Solebury Capital where he focuses on the healthcare sector. Before joining Solebury in 2019, John worked in equity capital markets for 15 years most recently as a Managing Director at Jefferies. Prior to…

Presentations and Panels
IPO Readi­ness: Suc­cess Fac­tors and Se­crets and Best Prac­tices for Eu­ro­pean For­eign Pri­vate Is­suers
Webcast
E0d781b039a088107db919449b7cf8e2_72606f373c2bbb09b5f38b76baffd2ca_120_120
Ernst & Young
Dr. Martin Steinbach, Partner, Head of IPO and Listing Services / Ernst & Young
A partner at one of the EY member firms in Germany, Martin is the EY EMEIA IPO Leader as well as the Head of IPO and Listing Services for EY GSA (Germany, Switzerland and Austria). He focuses on IPOs, investor relations, mergers and acquisitions, and…
3200c51d291d86bce0227d13913a1e45_a6ab6b4d707632c45ba4a0e754dab33b_120_120
Deutsche Bank AG
Joseph Oakenfold, Vice President / Deutsche Bank AG
Joe Oakenfold is the lead salesperson for Deutsche Banks‘ Depositary Receipts business in Europe bringing corporate issuers to the US capital markets and enabling access to the worlds’ largest pool of investment. With over 20 years’ experience, Joe…
593ba57538cd58097ce87761be09e194_862565ccd9dc73b04ad9b89945b9a28d_120_120
Ernst & Young
Dirk Gallowsky, Partner / Ernst & Young
Ernst & Young Limited is a global leader in assurance, tax, transaction and advisory services.
Bf2da8e0af1936ecb02d058ad2f814c7_27803bfc6395f82b0459c1e3be9cd4ea_120_120
NautaDutilh
Paul van der Bijl / NautaDutilh
Paul van der Bijl specializes in ECM transactions, public M&A, corporate governance of listed companies, anti-takeover defenses and complex cross-border transactions. Paul has acted as issuer’s counsel in the Nasdaq IPOs of CureVac…
Export to Excel